Immatics Reports Clinical Responses across Multiple Solid Tumor Types in Ongoing ACTengine® IMA203 Phase 1a Trial Targeting PRAME
- Dose escalation for cell therapy candidate ACTengine® IMA203 ongoing; dose level 3 completed at doses below 1 billion transduced cells
- Objective responses (RECIST 1.1) observed in 8/16 patients (50%) across multiple solid cancer types, with 8/13 responders (62%) treated at dose levels 2 and 3
- High T cell engraftment and persistence; clinical response associated with tumor infiltration
- Transient and manageable treatment-emergent adverse events; no higher-grade cytokine release syndrome or neurological toxicities observed
- IMA203 clinical data will be presented as late-breaking oral presentation at the SITC Annual Meeting on Saturday, November 13 at 12:00 pm EST
Immatics N.V. (“Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced an interim clinical data update from its TCR-engineered cell therapy (TCR-T) approach ACTengine® IMA203 targeting PRAME.